KIT2014 cleared its first human safety study with no measurable systemic exposure, but Kither Biotech must now prove that its peptide can improve lung function and inflammation in patients.
PERT is old, essential and burdensome. Blackstone’s $250m Anagram bet asks whether ANG003 can reset enzyme therapy.
See how RELiZORB improved weight and BMI z-scores in tube-fed children aged 1–5 in new real-world data. Explore what this means for pediatric care today.
Clarametyx’s CMTX-101 showed strong early signals in cystic fibrosis. Find out what this means for chronic lung infections and future bronchiectasis care.